A nanoparticle drug delivery system using the neuropeptide Substance P to target tumors delivered the chemotherapy drug 5-FU with high specificity, achieving 60.2% tumor inhibition in mice while sparing healthy cells.
60.2% tumor inhibitionSubstance P-targeted dendritic nanoparticles carrying 5-FU achieved this tumor inhibition rate in mouse models while selectively sparing normal cells
What the researchers found
The dendritic theranostic agent P-FU 4, which combines Substance P targeting with four 5-FU drug molecules and a near-infrared imaging dye, demonstrated several key outcomes: 16% drug loading capacity, dose-dependent cytotoxicity against cancer cells with minimal effect on normal cells, preferential uptake by tumor cells through NK1R-mediated interaction, and 60.2% tumor inhibition rate in a mouse model.
The nanoparticle self-assembled from the dendritic construct, and the dendron architecture prevented the fluorescent dye from aggregation-mediated quenching, maintaining strong near-infrared signal for real-time monitoring of drug distribution.
Why it matters
A major challenge in chemotherapy is getting drugs to tumors without damaging healthy tissue. By using the neuropeptide Substance P as a guided missile to seek out NK1 receptors on tumor cells, this approach delivers drugs more precisely. The built-in imaging capability allows doctors to see where the drug accumulates in real time, combining diagnosis and treatment in a single platform.
How the study worked
Researchers designed a dendritic molecular construct using lysine branch points to conjugate four 5-FU molecules, Substance P (as the tumor-targeting ligand), and a near-infrared squaraine dye onto a single platform. The construct self-assembled into nanoparticles. In vitro cytotoxicity was tested against cancer and normal cell lines. In vivo studies used a mouse tumor model (BALB/c nude mice) to assess tumor inhibition and near-infrared fluorescence imaging.
What this study cannot tell us
The 60.2% tumor inhibition rate, while significant, means substantial tumor growth continued. The study used nude mouse xenograft models, which lack normal immune function and may not predict human responses. Long-term toxicity, pharmacokinetics, and biodistribution were not fully characterized. NK1R expression varies across tumor types, limiting this approach to NK1R-positive cancers. Scale-up manufacturing of the complex dendritic construct could be challenging.
How to read the evidence
This is a preclinical study combining in vitro cell experiments with in vivo mouse tumor models. While the results demonstrate proof-of-concept with quantitative tumor inhibition data, translation to human clinical use requires extensive further development and testing.
When this study was published
Published in 2017 in Biomaterials, a high-impact journal. This represents an established concept in peptide-targeted drug delivery, and the Substance P/NK1R targeting strategy continues to be developed by multiple research groups.
The bigger picture
This study showcases the versatility of neuropeptides as targeting agents for cancer drug delivery. The Substance P/NK1R system joins a growing list of peptide-receptor pairs being exploited for precision oncology. The theranostic approach — combining therapy and diagnostics in one molecule — represents the frontier of personalized cancer treatment where clinicians can simultaneously treat and monitor drug delivery.
Questions still open
- Which human cancer types express enough NK1R to make Substance P-targeted drug delivery clinically viable?
- Could this dendritic platform be adapted to carry newer, more potent anticancer agents beyond 5-FU?
- How does the tumor-inhibition rate compare to antibody-drug conjugates targeting the same tumors?
Common questions
Why use Substance P to deliver cancer drugs?
What does 'theranostic' mean in this context?
Read the original research
Real-time near-infrared bioimaging of a receptor-targeted cytotoxic dendritic theranostic agent.
Biomaterials, 120, 1-10
Citation
Wu, Junchen; Zhou, Yuren; Li, Shang; Qu, Dahui; Zhu, Wei-Hong; Tian, He. (2017). Real-time near-infrared bioimaging of a receptor-targeted cytotoxic dendritic theranostic agent.. Biomaterials, 120, 1-10. https://doi.org/10.1016/j.biomaterials.2016.11.011